Koninklijke Philips NVRYLPF -0.63%72 3-Year EBITDA Growth Rate is 181.60% as of Mar. 2026, which is 90700% above its 10-year median of 0.20. GuruFocus rates RYLPF with a GF Scoreâ„¢ of 72/100 and a GF Valueâ„¢ of $26.02 (Fairly Valued). The stock has 3 warning signs investors should review. Among 694 Medical Devices & Instruments companies, Koninklijke Philips NV ranks better than 99.86% on this metric.
During the past 12 months, Koninklijke Philips NV's average EBITDA Per Share Growth Rate was -7.70% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 181.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 5.30% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was -6.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Koninklijke Philips NV was 181.60% per year. The lowest was -64.90% per year. And the median was 0.20% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Koninklijke Philips NV 3-Year EBITDA Growth Rate Related Terms
RYLPF vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Koninklijke Philips NV's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Koninklijke Philips NV 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Koninklijke Philips NV's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Koninklijke Philips NV's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 181.60% mean?
Koninklijke Philips NV (RYLPF) has a 3-Year EBITDA Growth Rate of 181.60% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Koninklijke Philips NV and its competitors. This is 90700% above median its historical median of 0.20. According to the industry distribution chart, Koninklijke Philips NV ranks #1 out of 694 companies in the Medical Devices & Instruments industry, placing it in the top 0.099999999999994%.
Is Koninklijke Philips NV's 3-Year EBITDA Growth Rate too high?
Koninklijke Philips NV's current 3-Year EBITDA Growth Rate of 181.60% is 90700% above median its 10-year median of 0.20. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.65. Koninklijke Philips NV's value of 181.60% is 2273.9% above this industry median. Based on the distribution chart, Koninklijke Philips NV ranks #1 out of 694 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Koninklijke Philips NV has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Koninklijke Philips NV's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Koninklijke Philips NV ranks #1 out of 694 companies for 3-Year EBITDA Growth Rate. This places Koninklijke Philips NV in the top 0% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.65. Koninklijke Philips NV's value of 181.60% is 2273.9% above this benchmark. While the company's 10-year median is 0.20 vs. the industry median of 7.65, Koninklijke Philips NV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.65, based on 694 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Koninklijke Philips NV's current 3-Year EBITDA Growth Rate of 181.60% is 2273.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Koninklijke Philips NV and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Koninklijke Philips NV's current 3-Year EBITDA Growth Rate is 181.60%, which is 90700% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Koninklijke Philips NV stock overvalued right now?
Based on GuruFocus' analysis, Koninklijke Philips NV (RYLPF) is currently considered Fairly Valued. The stock's GF Value™ is $26.02, compared to a current price of $27.84 — trading 7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 181.60%, which is 90700% above median its 10-year median of 0.20 and 2273.9% above the Medical Devices & Instruments industry median of 7.65. Koninklijke Philips NV's overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Koninklijke Philips NV (RYLPF), the current 3-Year EBITDA Growth Rate is 181.60% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Koninklijke Philips NV (RYLPF) Overvalued in 2026?
Based on GuruFocus' analysis, Koninklijke Philips NV stock appears to be overvalued.
The current stock price of $27.84 is trading 7% above its estimated GF Value™ of $26.02.
GuruFocus considers Koninklijke Philips NV to be Fairly Valued.
Key valuation signals for RYLPF:
3-Year EBITDA Growth Rate: 181.60% (90700% above median its 10-year median of 0.20)
GF Value™: $26.02 vs. price of $27.84 (7% above fair value)
Industry Position: 2273.9% above the Medical Devices & Instruments median (#1 of 694)
No single metric tells the full story. See the RYLPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Koninklijke Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. Nearly 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound and X-ray equipment, and image-guided therapy solutions. The connected care segment (under 30% of revenue) encompasses monitoring and analytics systems for hospitals, informatics business, and also houses the sleep and respiratory care segment. Personal health business (remainder of revenue) is mainly oral health and personal care product lines, which include electric toothbrushes and men's grooming and personal-care products.
72GF Score
Get the complete analysis for RYLPF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RYLPF has been successfully added to your 